Sector News

Merck KGaA’s deputy chief Oschmann set to become CEO – Manager Magazin

March 20, 2015
Life sciences
(Reuters) – Germany’s Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.
 
The publication said Oschmann, 57, would take on the new role after the group’s annual shareholder meeting in April 2016 or in September next year at the latest, when Kley’s current contract expires.
 
The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January, sharing strategic management functions and representation of the company with Kley, who is 63.
 
A Merck spokeswoman said a decision on Kley’s succession has not yet been made and that this would be a matter for the family-controlled group’s board of partners. She declined to comment further.
 
Merck, which is also the world’s largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich , putting it on track to become the world’s second-largest lab supplies maker after Thermo Fisher.
 
Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc’s emerging markets operations. The two companies share historic roots but are under separate ownership since World War One. (Reporting by Georgina Prodhan; Editing by Ludwig Burger and Greg Mahlich)

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach